High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast cancer: results of comprehensive re-evaluation of multi-institutional case series.

[1]  Hengqiang Zhao,et al.  The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status , 2021, Frontiers in Oncology.

[2]  R. Boidot,et al.  ER−/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple‐negative breast cancer , 2021, International journal of cancer.

[3]  A. Özgüzer.  THE SMALLEST SUBTYPE IN THE SEER DATABASE: ESTROGEN RECEPTOR NEGATIVE PROGESTERONE RECEPTOR POSITIVE BREAST CANCER , 2021 .

[4]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Ren,et al.  Clinicopathological Characteristics and Breast Cancer–Specific Survival of Patients With Single Hormone Receptor–Positive Breast Cancer , 2020, JAMA network open.

[6]  E. Fukuma,et al.  Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining , 2018, Breast Cancer.

[7]  W. Biernat,et al.  Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact? , 2018, Cancer treatment reviews.

[8]  Stephen B. Edge,et al.  Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer , 2018, Annals of Surgical Oncology.

[9]  M. Troxell,et al.  Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data. , 2017, Archives of pathology & laboratory medicine.

[10]  P. Tan,et al.  Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group , 2016, Journal of Clinical Pathology.

[11]  E. Kornaga,et al.  Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort , 2016, Modern Pathology.

[12]  E. Kornaga,et al.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort , 2016, Modern Pathology.

[13]  Yang Luo,et al.  Prognostic Significance of Single Progesterone Receptor Positivity , 2015, Medicine.

[14]  Keda Yu,et al.  Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer , 2015, BMC Medicine.

[15]  F. Sanschagrin,et al.  Validation of EP1 Antibody Clone for Estrogen Receptor Immunohistochemistry in Breast Cancer , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  Andrew H. Beck,et al.  Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype , 2013, Breast Cancer Research.

[17]  S. Badve,et al.  EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor α , 2013, Journal of Clinical Pathology.

[18]  A. Sapino,et al.  Comparison of anti-estrogen receptor antibodies SP1, 6F11, and 1D5 in breast cancer: lower 1D5 sensitivity but questionable clinical implications. , 2012, American Journal of Clinical Pathology.

[19]  Z. Maleki,et al.  ER-negative /PR-positive breast carcinomas or technical artifacts in immunohistochemistry? , 2012, Archives of Iranian medicine.

[20]  N. Udvarhelyi,et al.  Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they? , 2011, Pathology & Oncology Research.

[21]  A. Richardson,et al.  A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results. , 2009, American journal of clinical pathology.

[22]  Keda Yu,et al.  Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment , 2008, Journal of Cancer Research and Clinical Oncology.

[23]  E. van Limbergen,et al.  Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[25]  C. Gomez-Fernandez,et al.  Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. , 2005, American journal of clinical pathology.

[26]  Susan G. Hilsenbeck,et al.  Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates , 2004, Clinical Cancer Research.

[27]  C. Clarke,et al.  Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells. , 1999, Molecular endocrinology.